Myelin-oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin (Ig) superfamily, exclusively expressed in the central nervous system (CNS). MOG is an intrinsic membrane protein characterized by a N-terminal extracellular immunoglobulin- like variable (Ig-like V-type) domain, two hydrophobic transmembrane domains and a cytoplasmic C-terminal region. The N-terminal MOG domain has strong homology with the N- terminus of butyrophilin, a protein expressed in the lactating mammary gland. Human MOG gene is localized to chromosome 6p22-p21.3 (band C of mouse chromosome 17) at the distal end of the MHC class Ib region. Despite the similar names, oligodendrocyte-myelin glycoprotein (OMG) is a separate protein encoded within a large intron of the NF1 gene. The 2 glycoproteins are associated specifically with oligodendrocytes and myelin, but have quite different roles in myelinogenesis and are structurally unrelated. MOG is an intrinsic membrane molecule with 2 transmembrane domains, whereas OMG is anchored in the outer leaflet of the plasma membrane through a glycophospholipid tail. OMG belongs to the family of proteins with a series of tandem leucine-rich repeats, while MOG is a member of the Ig superfamily.MOG contains nine exons and eight separating introns, giving rise to at least eight alternatively spliced variants encoding for the MOG-alpha1-4 and MOG-beta 1-4 isoforms (16-26kD). The different MOG isoforms may interact to form homo- and heterodimers and trimers (55 and 78kD). During the last step of myelinogenesis, MOG is expressed in the CNS on the outermost surface (external lamella) of mature myelin sheaths and on the cell surface of myelinating oligodendrocytes. MOG is thought to function as a regulator of oligodendrocyte microtubule stability and as a mediator of interactions between myelin and the immune system in the complement cascade. Although MOG is a relatively minor component of the myelin membrane, it is a primary auto- antigen target involved in the pathogenesis of immune-mediated demyelinating diseases including experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis.The MOG 35-55 peptide is an immunodominant epitope of MOG that induces strong T and B cell responses. A single injection of this peptide fragment can produce an exacerbating-remitting neurologic disease with extensive plaque-like demyelination, which may serve as a model for investigating multiple sclerosis.Applications:Suitable for use in ELISA. Western Blot, though not tested, may potentially be used as an application. Other applications not tested.Recommended Dilution:ELISA: 0.1-2ug/mlWestern Blot: 1-5ug/mlOptimal dilutions to be determined by the researcher.Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
|Catalog ID||M9758-08A-100UL||Supplier Catalog ID||M9758-08A|
|Size||100 µl||Price||$ 715.00|
|Supplier||United States Biological Inc.||Package Content||Rabbit Anti-human MOG polyclonal antibody SKU:M9758-08A, 100 µl|
|Isotype||IgG||Immunogen||Synthetic peptide corresponding to 17aa from the C-terminus of human MOG (KLH).|
|Specificity||Recognizes human MOG.||Dilution||ELISA: 0.1-2ug/mlWestern Blot: 1-5ug/ml Optimal dilutions to be determined by the researcher.|
|Purification Method||Purified by immunoaffinity chromatography.||Gene||MOG|
|Shipping Temperature||Blue Ice||Storage & Handling||-20°C|
For research use only.